Review of first-in-human trials should safeguard the integrity of the scientific enterprise through a focus on preclinical and clinical study quality.
No takes yet. Share an insight, caveat, or question.
London et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: